Abstract
Hexokinases (HKs) convert hexose sugars to hexose-6-phosphate, thus trapping them inside cells to meet the synthetic and energetic demands. HKs participate in various standard and altered physiological processes, including cancer, primarily through the reprogramming of cellular metabolism. Four canonical HKs have been identified with different expression patterns across tissues. HKs 1–3 play a role in glucose utilization, whereas HK 4 (glucokinase, GCK) also acts as a glucose sensor. Recently, a novel fifth HK, hexokinase domain containing 1 (HKDC1), has been identified, which plays a role in whole-body glucose utilization and insulin sensitivity. Beyond the metabolic functions, HKDC1 is differentially expressed in many forms of human cancer. This review focuses on the role of HKs, particularly HKDC1, in metabolic reprogramming and cancer progression.
Funding Information
  • U.S. Department of War (W81XWH2010650, I01BX00382, R01 DK104927, R01 DK111848, U01 DK127378, P30 DK020595)
  • VA Merit Review Award (W81XWH2010650, I01BX00382, R01 DK104927, R01 DK111848, U01 DK127378, P30 DK020595)
  • National Institutes of Health (W81XWH2010650, I01BX00382, R01 DK104927, R01 DK111848, U01 DK127378, P30 DK020595)

This publication has 170 references indexed in Scilit: